Generation of broadly neutralizing antibodies for the development of an enterovirus immunotherapy

Withdrawn

• Conditions: enterovirus infections; viral infections; 10047438

• Registration Number: NL-OMON45608
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 25

Inclusion Criteria

Age of 18-65 yrs.
Healthy condition (no immunodeficiency).
Written informed consent.

Exclusion Criteria

see above

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>From each donor blood will be withdrawn in order to collect serum and PBMCs.<br /><br>The sera will be used to determine nAb titers against a panel of clinically<br /><br>relevant EVs, using a cytopathic effect (CPE) reduction assay. On the basis of<br /><br>the neutralizing activity in the sera, paired PBMC samples will be selected for<br /><br>isolation of bNAb producing B cells by single cell sorting. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>None</p><br>